Evommune, Inc. (EVMN) Stock Price & Analysis
Evommune, Inc. (EVMN) rose 1.49% to USD 20.49 as of June 10, 2026 at 02:39 UTC, according to Nexqual real-time market data.
EVMN last closed at USD 20.19; the session ranged USD 19.43–21.08 on volume of 378,887 shares. Market capitalization is $738.02M, with a 52-week range of USD 13.89–33.2 (NYQ). Source: Nexqual, June 10, 2026 at 02:39 UTC.
Key Statistics (as of June 10, 2026 at 02:39 UTC)
| Price | USD 20.49 |
|---|---|
| Change | ▲ 1.49% (up) |
| Previous Close | USD 20.19 |
| Open | USD 20.21 |
| Day Range | USD 19.43 – 21.08 |
| 52-Week Range | USD 13.89 – 33.2 |
| Volume | 378,887 shares |
| Market Cap | $738.02M |
| Exchange | NYQ |
Technical Analysis (EVMN)
Nexqual's technical model rates EVMN "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:39 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.29 (neutral) |
| vs SMA50 | Below (USD 23.87) |
| MACD | -1 (negative) |
Analyst Ratings (EVMN)
Wall Street analysts rate EVMN "Strong Buy" based on 8 analysts, with a mean price target of USD 52.25 (range USD 50–55), per Nexqual as of June 10, 2026 at 02:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 52.25 |
| High Target | USD 55 |
| Low Target | USD 50 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (EVMN)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.67 |
| Revenue Estimate | $1.03M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -1.43 vs est -0.84 ▼ miss |
| 2025-09-30 | USD -8.07 vs est -11.36 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Financials & Fundamentals (EVMN)
| Total Revenue | $10.00M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -899.93% |
| Profit Margin | +0.00% |
| ROE | -44.95% |
| Debt / Equity | 2.99 |
| Current Ratio | 20.36 |
| Total Cash | $211.46M |
| Total Debt | $9.11M |
| Free Cash Flow | $-57.53M |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Financial Health Score (EVMN)
Nexqual rates Evommune, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:39 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $211M cash vs $9M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$58M, burning cash |
| Efficiency | Critical — ROE -45%, ROA -29.7% |
Ownership (EVMN)
| Insider Ownership | +7.91% |
|---|---|
| Institutional Ownership | +110.79% |
| Shares Outstanding | 36.02M |
| Float | 19.98M |
| Short % of Float | +16.40% |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Leadership (EVMN)
Evommune, Inc. is led by Luis C. Pena (age 62), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 02:39 UTC.
| Founder, President, CEO & Director | Luis C. Pena (age 62) |
|---|---|
| Chief Financial Officer | Kyle Carver (age 37) |
| Co-Founder, Chief Medical Officer & Director | Eugene Andrew Bauer (age 83) |
| Chief Scientific Officer | Jeegar Patel (age 47) |
| Senior Vice President of Technical Operations | Lou Sehl |
Major Backers & Investors (EVMN)
Notable institutional backers of Evommune, Inc. include Eqt Fund Management S.a R.l., RA Capital Management, L.P., JPMorgan, according to Nexqual as of June 10, 2026 at 02:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Eqt Fund Management S.a R.l. | 13.69% |
| RA Capital Management, L.P. | 9.7% |
| JPMorgan | 6.31% |
| Pivotal bioVenture Partners Investment Advisor, LLC | 5.35% |
| Andera Partners | 5.27% |
| RTW Investments LP | 4.17% |
| MPM Bioimpact LLC | 4.04% |
| Nan Fung Group Holdings Limited | 4% |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
From Evommune, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
- The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
- Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALMS | Alumis Inc. | USD 20.01 | ▲ 4.98% |
| MPLT | MapLight Therapeutics, Inc. | USD 29.27 | ▲ 4.5% |
| MAZE | Maze Therapeutics, Inc. | USD 23.93 | ▼ 1.4% |
| SYRE | Spyre Therapeutics, Inc. | USD 76.44 | ▲ 3.79% |
| LBRX | LB Pharmaceuticals Inc | USD 29.27 | ▲ 2.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:39 UTC. This page is informational and not investment advice.